Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients

Summary

Direct oral factor inhibitors (DOFIs) are an attractive alternative to vitamin K antagonists (VKA) for the treatment of patients with antiphospholipid syndrome (APS). In the absence of prospective, randomised trial data, reports of therapeutic failures in clinical practice alert clinicians to potential limitations of DOFI therapy for this indication. Data for all cases were collected from a centralised system that contains complete medical records of all patients treated and followed at Mayo Medical Center. We present here three consecutive APS patients who had had no thromboembolism recurrence on warfarin but were switched to DOFIs. The diagnosis of APS was established according to currently recommended criteria. The three cases were as follows: A woman with primary APS developed thrombotic endocarditis with symptomatic cerebral emboli after transition to dabigatran. A second woman with primary APS experienced ischemic arterial strokes and right transverse-sigmoid sinus thrombosis after conversion to rivaroxaban. A man with secondary APS suffered porto-mesenteric venous thrombosis after switching to rivaroxaban. None of these patients had failed warfarin prior to the transition to DOFIs. Based on these three cases, we advocate caution in using DOFIs for APS patients outside of a clinical trial setting, until further data becomes available.

Keywords

Direct oral anticoagulants - warfarin - antiphospholipid syndrome - thromboembolic complications

• References

• 1 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
• 2 Meroni PL, Borghi MO, Raschi E. et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7: 330-339.
• 3 Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I. et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206-218.
• 4 Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. J Am Med Assoc 2006; 295: 1050-1057.
• 5 Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57: 1487-1495.
• 6 Garcia D, Akl EA, Carr R. et al. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013; 122: 817-824.
• 7 Ketha SS, Pruthi RK, McBane RD. et al. Lupus anticoagulant, warfarin, and alternative laboratory monitoring of anticoagulation. J Thromb Thrombolysis. 2013 Epub ahead of print.
• 8 European Medicines Agency - - Xarelto (Internet). (cited 2014 Mar 5). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicineshuman/medicines/000944/human_med_001155.jsp
• 9 Press Announcements > FDA expands use of Xarelto to treat, reduce recurrence of blood clots (Internet). (cited 2014 Mar 5). Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm
• 10 European Medicines Agency - - Pradaxa (Internet). (cited 2014 Mar 5). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicineshuman/medicines/000829/human_med_000981.jsp
• 11 Press Announcements > FDA approves Pradaxa to prevent stroke in people with atrial fibrillation (Internet). (cited 2014 Mar 5). Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm
• 12 Tahir F, Riaz H, Riaz T. et al. The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature. Thromb J 2013; 11: 18.
• 13 Arachchillage DJ, Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 2013; 15: 331.
• 14 ISRCTN68222801 - Rivaroxaban in Antiphospholipid Syndrome (RAPS) (Internet). (cited 2014 Mar 5). Available from: http://www.controlled-trials.com ISRCTN68222801
• 15 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
• 16 Crowther MA, Ginsberg JS, Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the anti-phospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
• 17 Finazzi G, Marchioli R, Brancaccio V. et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-853.